Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) EPS (Weighted Average and Diluted) (2022 - 2025)

Dianthus Therapeutics (DNTH) has 4 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.97 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) fell 31.08% year-over-year to -$0.97; the TTM value through Sep 2025 reached -$3.5, down 148.48%, while the annual FY2024 figure was -$2.55, 69.82% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.97 in Q3 2025 per DNTH's latest filing, down from -$0.89 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $8.95 in Q4 2023 and bottomed at -$22.99 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$3.56, with a median of -$0.82 recorded in 2025.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 138.93% in 2023, down 4293.1% in 2023.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$22.99 in 2022, then skyrocketed by 138.93% to $8.95 in 2023, then tumbled by 109.16% to -$0.82 in 2024, then decreased by 18.29% to -$0.97 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.97 in Q3 2025, -$0.89 in Q2 2025, and -$0.82 in Q1 2025.